All In Biotech

Drug Trial Radar · NCT05475184

A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

A Multicenter, Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of JPI-547, a PARP/TNKS Dual Inhibitor in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Last checked: Nov 19, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

58

Planned (sponsor's estimate)

Start

Aug 31, 2022

Primary completion

Nov 2024

Study completion Jun 2025

Sponsor

Lead sponsor
Onconic Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jul 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer subjects previously treated with a PARP inhibitor

Conditions

  • Ovarian Cancer

Interventions

  • JPI-547Drug

    Poly-(ADP-ribose) polymerase (PARP) \& tankyrase (TNKS) inhibitor. * The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle. * 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate(ORR)Time frame: From date of study enroll until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center

    Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.